ArticleAntimicrobial agents and chemotherapy2021
Atypical Molecular Basis for Drug Resistance to Mitochondrial Function Inhibitors in Plasmodium falciparum.
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Efficacy, Structure-Activity Relationship, and Mode of Action Studies of a New Generation of Acridine/Acridone-Based Antimalarials.ACS infectious diseases · 2026Article
- Novel heterospirocyclic antimalarials with activity against artemisinin- and multidrug-resistant P. falciparum malaria.International journal for parasitology. Drugs and drug resistance · 2025Article
- Identification of genetic variations linked to buparvaquone resistance in Theileria annulata infecting dairy cattle in India.PloS one · 2025Article
- Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome b.European journal of medicinal chemistry · 2024Article
- Dobinin K Displays Antiplasmodial Activity through Disruption ofMolecules (Basel, Switzerland) · 2024Article
- 7-ACS infectious diseases · 2023Article
- Article
- Structure-activity relationships ofExpert opinion on drug discovery · 2022Article
- Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.Journal of medicinal chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Heather J PainterDepartment of Biochemistry and Molecular Biology, Huck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania, USA heather.painter@fda.hhs.gov manuel@psu.edu.ORCID 0000-0003-0264-4689
Joanne M MorriseyCenter for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Michael W MatherCenter for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-1062-0137
Lindsey M OrchardDepartment of Biochemistry and Molecular Biology, Huck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania, USA.ORCID 0000-0003-1295-3733
Cuyler LuckDepartment of Biochemistry and Molecular Biology, Huck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania, USA.ORCID 0000-0002-1150-0057
Martin J SmilksteinMedical Research Service, Department of Veterans Affairs Medical Center, Portland, Oregon, USA.ORCID 0000-0002-4701-1722
Michael K RiscoeMedical Research Service, Department of Veterans Affairs Medical Center, Portland, Oregon, USA.ORCID 0000-0002-1343-5279
Akhil B VaidyaCenter for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-1063-5571
Manuel LlinásDepartment of Biochemistry and Molecular Biology, Huck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania, USA heather.painter@fda.hhs.gov manuel@psu.edu.ORCID 0000-0002-6173-5882
Pennsylvania State University · USDrexel University · US
Funding
Spatial Patterning During DevelopmentP50GM071508 · NIGMS · PRINCETON UNIVERSITY · PI COX, EDWARD C · 2004 to 2013
$30.6MORGANELLE GENOMES OF MALARIAL PARASITESR01AI028398 · NIAID · MCP HAHNEMANN UNIVERSITY · PI AKHIL B VAIDYA · 1989 to 2026
$10.1MOptimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0MMolecular Pathways Affected by Drugs that Disrupt Na+ Homeostasis in Malaria ParasitesR01AI132508 · NIAID · DREXEL UNIVERSITY · PI AKHIL B VAIDYA · 2017 to 2026
$5.7MDevelopment of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2MDevelopment of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7MNovel antimalarial strategies using metabolomic network discoveryDP2OD001315 · OD · PRINCETON UNIVERSITY · PI LLINAS, MANUEL · 2007 to 2007
$2.4MMolecular Pathways Targeted by Potent Antimalarial Pyrazole CompoundsR01AI098413 · NIAID · DREXEL UNIVERSITY · PI VAIDYA, AKHIL B · 2012 to 2015
$1.9MOptimizing ELQs for Treatment and Prevention of MalariaR56AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2012 to 2012
$574kBLR&D Research Career Scientist Renewal Award ApplicationIK6BX004857 · VA · PORTLAND VA MEDICAL CENTER · PI Michael Kevin RISCOE · 2020 to 2026
–Pharmachin Optimization and TestingI01BX003312 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2016 to 2025
–Optimizing Pharmachins for Treatment and Prevention of Drug Resistant MalariaI01BX001421 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2012 to 2015
–BLRD VA I01 BX001421BLRD VA I01 BX003312BLRD VA IK6 BX004857NIAID NIH HHS R01 AI028398NIAID NIH HHS R01 AI098413NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI132508NIAID NIH HHS R01 AI141412NIAID NIH HHS R56 AI100569NIGMS NIH HHS P50 GM071508NIH HHS DP2 OD001315
Abstract
The continued emergence of drug-resistant
Indexed as
AntimalarialsMalaria, FalciparumDNA Copy Number VariationsDrug ResistanceHumansMitochondriaPlasmodium falciparumAntimalarialsantimalarial agentsdrug resistancemalariametabolismPlasmodiumPlasmodium falciparum
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.